Reading MIRM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MIRM free→Reading MIRM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MIRM free→QuarterlyIQ Insights · MIRM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry Into a Material Definitive Agreement. Indenture and Notes On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million aggregate principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of May 15, 202…
The Notes were issued to the initial purchasers in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), in transactions not involving any public offering. The Notes were resold by the initial purchasers to persons whom the initial purchasers reasonably believe are “qualified institutional buyers,” as defined in, and in accordance with, Rule 144A under the Securities Act. The Company relied on these exemptions from registration based in part on repres…
Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement. The disclosure set forth in
Results of Operations and Financial Condition. On May 6, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Sec…
Other Events. On May 4, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter (“IBAT”) inhibitor, in patients with primary sclerosing cholangitis (“PSC”). The VISTAS Phase 2b study included 158 patients with PSC who were assigned to either a primary analysis cohort (moderate to severe itch; n=111) or a secondary analysis cohort (mild itch; n=47) based on it…
Other Events. On April 27, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). The Phase 2b portion of the AZURE-1 study included the first 53 patients evaluated at Week 24 of treatment. At Week 24, treatment with brelovitug demonstrated rob…
Results of Operations and Financial Condition. On February 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” f…
Completion of Acquisition or Disposition of Assets. On January 23, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) completed the previously announced acquisition of Bluejay Therapeutics, Inc., a Delaware corporation (“Target”), contemplated by the Agreement and Plan of Merger and Reorganization, dated December 6, 2025 (the “Merger Agreement”), by and among the Company, Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub I”), Bjor…
Other Events. Immediately following the consummation of the Mergers, the Company closed the two private placement offerings (the “Private Placements”) pursuant to the two subscription agreements entered into by the Company with the parties thereto on December 7, 2025 and December 18, 2025, as previously announced in the Company’s Current Reports on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “Commission”) on December 8, 2025 and December 19, 2025 . As of January 23,…
Results of Operations and Financial Condition. On January 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release announcing, among other things, the Company's preliminary unaudited net product sales for the fiscal year ended December 31, 2025, preliminary unaudited net product sales of LIVMARLI (maralixibat) and CHOLBAM and CTEXLI, and preliminary unaudited cash, cash equivalents and investments. The full text of the press release is furnished as Exhibit 99.1 to this Cur…
by reference. Based in part upon the representations of the PIPE Investors in the Subscription Agreement, the offering and sale of the securities in the Private Placement will be made in reliance on the exemptions afforded by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of applicable state securities or “blue sky” laws. The PIPE Investors represented that they are accredited investors, as such term is…
Entry into a Material Definitive Agreement. On December 18, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with entities associated with TCG Crossover Management, LLC (“TCGX”), an institutional investor (the “PIPE Investors”), pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately following the Closing (as defined below), 1,000,000 share…
Other Events. In November 2025, Mirum Pharmaceuticals, Inc. (the “Company”) announced that it received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Sandoz, Inc. (“Sandoz”), providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of a generic version of Livmarli ® (maralixibat). The Company subsequently received additional Notice Letters from Annora P…
Regulation FD Disclosure. On December 19, 2025, the Company issued a press release announcing its entry into the Subscription Agreement, a copy of which is furnished as Exhibit 99.1 to this Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities under, Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such inf…
by reference. Based in part upon the representations of the Target security holders in suitability documentation to be delivered by the Target security holders as a condition to receipt of their respective Stock Consideration, the issuance of the Stock Consideration will be issued in a transaction exempt from registration under the Securities Act by reason of Rules 504 and 506 of Regulation D promulgated under the Securities Act. The suitability documentation to be delivered by the Target sec…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger and Reorganization On December 6, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub I”), Bjork Merger Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of the Company (“Merger Sub…
Regulation FD Disclosure. On December 8, 2025, the Company issued a press release announcing its entry into the Merger Agreement and the Subscription Agreement, a copy of which is furnished as Exhibit 99.1 to this Form 8-K. In connection with the Private Placement, the Company presented a corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibits 99.1 and 99.2…
Other Events. The press release attached hereto as Exhibit 99.1 and the corporate presentation attached hereto as Exhibit 99.2 contain information relating to anticipated developments concerning the Company’s business and include the following disclosures: Company Update Assuming the Closing of the proposed Mergers, which the Company anticipates will occur in the first quarter of 2026, subject to regulatory approval and satisfaction or waiver of other customary closing conditions, the Company…
Other Events. On November 17, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Sandoz, Inc. (“Sandoz”) providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval to manufacture, use or sell a generic version of Livmarli® (maralixibat). In the Notice Letter, Sandoz alleges that five of the patents lis…
Results of Operations and Financial Condition. On November 4, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purpos…
Results of Operations and Financial Condition. On August 6, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of S…
Results of Operations and Financial Condition. On May 7, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Sec…
Results of Operations and Financial Condition. On February 26, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” f…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.